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Abstract
Implantation of a cranioplasty after osteoclastic craniotomy or craniectomy is one of the most common neurosurgical
procedures, and polymethylmethacrylate (PMMA) is one of the most frequently applied materials for cranioplasty. This report
describes the unique case of a patient with recurrent transitional meningioma WHO I that infiltrated the PMMA cranioplasty
7 years after primary surgery. We propose to restrict the use of porous PMMA as cranioplasty after the removal of convexity
meningioma.
INTRODUCTION
Remodeling the calvarial bone with freehand polymethyl-
methacrylate (PMMA) cranioplasty after craniectomy is a
very common neurosurgical procedure. Apart from freehand
PMMA application after decompressive hemicraniectomy or
postoperative osteomyelitis in stroke patients, some authors
have advocated the use of computer-assisted design and
computer-assisted manufacturing (CAD/CAM) cranioplasties
[1, 2], also after the removal of infiltrated skull or hyperostotic
bone in meningioma surgery [3, 4]. PMMA is one of the most
frequently applied materials for cranioplasty. To the best of
our knowledge, tumorous invasion of PMMA in a patient with
recurrent meningioma has never been reported. We describe
the case of a patient with recurrent meningioma WHO I that
infiltrated the implanted PMMA cranioplasty 7 years after
primary surgery.
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CASE REPORT
In 2012, the 45-year-old female patient presented at a neuro-
surgical department with aphasia and facial palsy. Magnetic
resonance imaging (MRI) showed a large space-occupying
tumor infiltrating the frontal bone. Consequently, the tumor
was removed, and histological workup confirmed a benign
meningiomaWHO I. Two years later, a CAD/CAM non-resorbable
biocompatible cranioplasty (BIOMET, Germany) composed
of PMMA spherical macro beads, coated and fused with
polyhydroxyethylmethacrylate, was implanted, see Fig. 1. Until
February 2018, consecutive MRIs had shown a tumor-free
area, and the clinical course had been uneventful. The MRI
conducted in February 2018 and the subsequentMRI in June 2019
(Fig. 2A and B) showed a progressive contrast-enhancing mass
along the falx cerebri that was strongly suspicious of recurrent
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Figure 1: Model of a CAD/CAM non-resorbable biocompatible cranioplasty
(Biomet, Germany) composed of polymethylmethacrylate (PMMA) spherical
macro beads coated and fused with polyhydroxyethylmethacrylate (PMHA).
to remove the tumorous mass along the falx. Before surgery,
computed tomography (CT) was carried out to visualize the
bony attachments of the PMMA cranioplasty (Fig. 2C). Neither
imaging modality had depicted any tumorous tissue inside
the cranioplasty. Thus, preoperatively, the cranioplasty was not
considered an area of tumor infiltration.
Revision surgery with the intent to remove the recurrent
meningioma was conducted in November 2019. The initial
PMMA cranioplasty that moderately adhered to the dura was
removed in one piece. After splitting of the cranioplasty, several
pieces were sent to the department of neuropathology because
of the surgeon’s strong impression that tumor tissue had
infiltrated the porous material of the cranioplasty. Further
surgerywas uneventful: the tumorwas dissected and completely
removed, the convexity durawas reconstructed, and a preformed
titanium cranioplasty was inserted. Histologically, the tumor
was confirmed as transitional meningioma WHO I.
Immunohistochemical analysis of meningioma cell
infiltration
The fragments were frozen in isopentane and embedded in Tis-
sue Tek® OCT compound (Sakura, Staufen, Germany). Samples
were cryosected and sections were fixed in 4% paraformalde-
hyde andwashed in phosphate buffered saline. To detectmenin-
gioma cell infiltration, cryosections were immunostained using
a human epithelial membrane antigen (EMA) specific mouse
monoclonal antibody (clone E 29, Agilent DAKO, Santa Clara, CA,
USA). To exclude glial cell infiltration, adjacent sections were
stained with a polyclonal rabbit anti-human glial fibrillary acidic
protein (GFAP) antibody (Agilent DAKO, Santa Clara, CA, USA).
To test for unspecific antibody binding, control sections were
incubated either in non-immunized mouse IgG (EMA staining)
or non-immunized rabbit IgG (GFAP staining) at identical protein
concentrations.
Pieces of the infiltrated cranioplasty were microscopically
examined after topical staining as described above. Immuno-
histology clearly identified meningioma cell formations inside
the cranioplasty (Fig. 3B and C), and topographical microscopy
showed meningioma formations along the preformed caverns
(Fig. 3A).
DISCUSSION
Only a few articles in the neurosurgical literature have focused
on tumor infiltration into the cranial flap. In 1994, Wester
described six patients undergoing reimplantation of tumor-
infiltrated autologous bone flaps after autoclaving. In 1997,
Vanaclocha et al. published their experiences in reimplanting
autoclaved bone flaps in 62 patients with various benign
and malignant skull-infiltrating tumors [5]. In the histological
evaluation of bone samples after the autoclaving procedure,
the authors found no living tumor cells inside the bone but
preserved mineral matrices. This finding, in combination with
the low rate of bone resorption during follow-up, resulted in
the authors’ conclusion that autoclaved calvarial bone flaps are
safe and feasible. It is noteworthy that no long-term follow-up
focusing on tumor regrowth or reinfiltration was provided in
this large series.
On the other hand, many large studies show a very high rate
of up to 25% of surgical revision after reimplantation of autolo-
gous bone flaps due to bone resorption [6, 7]. Themain reason for
replacing bones with artificial materials, such as PMMA, hydrox-
yapatite bioceramics, titanium and others, is aseptic bone necro-
sis [8, 9] that can be gradually visualized as a shrinking bone flap
in CT. Osteoconductive materials such as hydroxyapatite have
been intensively examined histologically. Bruno et al. reported
Figure 2: (A–C) Preoperative neuroimaging shows recurrent meningioma along the falx cerebri and under the cranioplasty (A: native CT scan, axial plane; B: contrast-
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Figure 3: (A–C) Histological work-up of the explanted cranioplasty: (A) hematoxylin/eosin staining, immunohistochemical staining for (B) epithelial membrane antigen,
and (C) GFAP (all ×20 magnification).
that neo-formed lamellar and trabecular bone tissue fragments
that are accompanied by amorphous reticular tissue showed
diffuse ossification in explanted bioceramic cranioplasties [10].
This intense osteo-conductive effect obviously facilitates the
osseous integration of artificial material into the skull; however,
invasive neoplastic engraftment may be potentially devastating,
particularly in recurrent skull-infiltrating bone tumors.
Currently, most neurosurgeons prefer the primary removal
of the potentially tumor-infiltrated autologous bone flap and
replacement with a CAD/CAM cranioplasty [1] or, at least, with
a simple PMMA reconstruction.
The most common skull-infiltrating tumor is meningioma,
most of which are graded WHO I. To the best of our knowledge,
no study has ever evaluated whether recurrent meningioma
has the propensity to infiltrate artificial materials covering and
integrating into the osteoclastic defect and, if so,whichmaterials
have a higher risk of meningioma growth. However, one cannot
necessarily assume that tumor growth inside the cranioplasty
is significant or results in more extensive tumor regrowth. It is
noteworthy that our findings in this unique case are in contrast
to the case report of Frassanito and co-workers who presented
the case of recurrent atypical meningioma that recurred without
infiltrating the hydroxyapatite cranioplasty [4].
However, we report this unique observation that resulted in
the departmental decision to stop reconstructing the skull with
any porous, bone-like, or osteoconductive material after menin-
gioma surgery. We now exclusively use titanium or a preformed
calcium phosphate composition whenever necessary and do not
reinsert the autoclaved autologous skull. Further in-vitro and in-
vivo studies are mandatory to shed light on the potential of
meningioma invasion into cranioplasty.
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